Byung-June Park @onco_park
Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect linkedin.com/in/oncopark/ Toronto, Canada Joined December 2019-
Tweets1K
-
Followers1K
-
Following7
-
Likes2K
Can mid-size molecules, particularly cyclic peptides, address challenges where antibodies and small molecules fall short? These molecules, which combine antibodies' targeting precision with small molecules' cell penetration, effectively engage intracellular "undruggable" targets.…
However, in the DESTINY-CRC01 trial, the ORR for patients with HER2 IHC 2+ / ISH- and HER2 IHC 1+ was 0%. In the DESTINY-PanTumor02 study, the number of patients evaluated as HER2 IHC 1+ or 0+ was very small, making it difficult to draw clear conclusions about the efficacy in…
However, in the DESTINY-CRC01 trial, the ORR for patients with HER2 IHC 2+ / ISH- and HER2 IHC 1+ was 0%. In the DESTINY-PanTumor02 study, the number of patients evaluated as HER2 IHC 1+ or 0+ was very small, making it difficult to draw clear conclusions about the efficacy in…
According to the press release, Ono Pharmaceutical's acquisition of Deciphera can be summarized in three main ways. Deciphera contributes specialized research and development capabilities in kinase drug discovery, robust commercial and sales platforms in the United States and…
Observing the 'spatial distribution' of responders and non-responders in DESTINY-Breast06 would be intriguing.
Observing the 'spatial distribution' of responders and non-responders in DESTINY-Breast06 would be intriguing.
Eunji Kwak @kej811
43 Followers 105 Following
Mika @Mika1482990572
23 Followers 107 Following 製薬開発pharmaceutical industry /抗がん剤Clinical Operation→次なにしようかな期/情報収集用/無言フォローすみません
Maria @mdobek19
1 Followers 23 Following
Chiquillos @chiquilloss
45 Followers 466 Following Gerçek sosyalizm İslam'dır.Komşun açken sen tok yatamazsın
Ji Hyun Kim @writ__e
329 Followers 409 Following National Cancer Center Korea clinical assistant professor (2024.3~), fellow (2021.3~2024.2), tweets are on my own
Abbas Kazimi @AbbasRKazimi
392 Followers 328 Following Chief Business Officer @NimbusTx. Biotech transactor & drug discovery enabler in the hope of getting patients better medicines. Tweets are solely my own views.
Highly Geared @HighlyGeared
52 Followers 251 Following
James Thetford @ThetfordJamie
64 Followers 200 Following
Becca J. Carlson @beccajcarlson
205 Followers 406 Following Associate @FlagshipPioneer • PhD @mit_hst @broadinstitute • Immunology, virology, microscopy, functional genomics
Ryan @ssh1226
14 Followers 64 Following
Zen is your friend @ZenTrader88
823 Followers 3K Following Think only when needed, otherwise just trust experience. Investing in stocks since 1997. This personal trading journal is not meant as investment advice.
Michael Roy @dr_mroy
149 Followers 281 Following Senior Scientist & Team Leader in Targeted Protein Degradation, Chemical Biology @WEHI_research 🦘 | Structural Biology & Drug Discovery | (Pseudo)kinases
Shilpa Pothapragada @shilpap_
449 Followers 857 Following 2023 @SchmidtFellows | @wyssinstitute | PhD from @TIFRH_buzz | Women’s Health | Organ-on-chip | Mechanobiology |
Kartik Sehgal @KartikSehgal_MD
807 Followers 1K Following Medical Oncologist @DanaFarber I Head & Neck + Immuno-Oncology I @AIIMS_nd @YaleIMed @BIDMChealth alumnusI Tweets = own opinions | RT ≠ endorsement I
Wangyang Tu @WangyangT
1 Followers 99 Following
Steven Corsello @corsellos
722 Followers 456 Following Medical oncologist and cancer researcher @[email protected]
LP @lp_arb
94 Followers 4K Following work in progress. lifelong learner. interested in law. financial markets. risk parity. tech.
Ian Ferguson @idferguson
218 Followers 710 Following Cancer Biology PhD student at Stanford in the Khavari Lab
Steven Cheng 程翔 @scheng23
456 Followers 1K Following Chemistry & chemical biology PhD candidate @NSF GRFP @Harvard Woo lab | Chemical engineering @Stanford alumnus
YI-Feng Zheng @pent1162
107 Followers 1K Following
Danny Buchan @zen_science
190 Followers 1K Following life is chemistry and miracles. Biotech Manager at Danaher/Phenomenex
Abbas Rizvi @aarizvi
182 Followers 926 Following Data Scientist. Genomics. Life long yearner. #rstats #billsmafia
Sam Klempner @KlempnerSam
3K Followers 652 Following GI medical oncologist focusing on stomach and esophageal cancer research at Massachusetts General Hospital, Harvard Medical School
Johnny Galtar @JohnnyGaltar
210 Followers 507 Following “Social Influencer” aka Underemployed. Twitter paroled since 5/17/2023 🐣
안윤근 @YG_Ahn05
0 Followers 2 Following
Akasha @akasha_purohit
14 Followers 339 Following
SG @SG90569292
1 Followers 1K Following
Alex_Smart @AlexSmartAU1
179 Followers 176 Following INVESTING IS SIMPLE IF YOU HAVE- "Vision to see, courage to buy and patience to hold"
Chai Bandlamudi @chaiband
181 Followers 284 Following Computational Biologist @sloan_kettering Assistant Member @MSKPathology
David S. Hong MD @DavidHongMD
3K Followers 933 Following MD Anderson Cancer Center medical oncologist, Deputy Chair of Dept. Investigational Cancer Therapeutics. Phase I clinical trials.Tweets are mine.
biotech12345 @biotech1235
10 Followers 51 Following
Melissalaw @melissa_law21
13 Followers 261 Following
H. Zhao @zhao_h
41 Followers 276 Following
Jacob J. Adashek, DO @jacobadashek
2K Followers 486 Following Med Onc fellow @HopkinsKimmel | Interested in biomarker-driven early phase clinical trials | Avid baker, reader, & sports fan | Tweets = my own
Faraz Salmasi @fsalmasi
258 Followers 793 Following Here for the #science | #OncPharm #TwitteRx | Tweets my own & no one else | not every retweet = endorsement | he/him 🏳️🌈 ally
artem morozov @artemmo30776735
11 Followers 110 Following
Asis Palazon @asispalazon
311 Followers 640 Following Group leader, Immuno-Oncology Lab at @CICbiogune
Cosmin Tudorache @cosmintud
1 Followers 2 Following
Lions Watson @LionsWatson
234 Followers 2K Following 01/28/13 Martin Mayhew & Brian Xanders develop draftdatabase. This is its fake account. @ Lions Watson for comedic insight to their thinking.
Dr Adil Daing Officia.. @dradiliqbaldain
596 Followers 4K Following Consultant Surgical Oncology And Robotic Surgery. Member American-ASCO,SSO And European ESMO Cancer Societies. Rt's Not Endorsements.
kvs069 @kvs069
34 Followers 157 Following
CT 888q @tho51274
0 Followers 63 Following
Pengyu Yang @Pengyu19
812 Followers 657 Following Ph.D., Drug Hunter @PlexiumTx | @scrippsresearch alum | #discoverychemistry | Drugging the #Undruggable | #chembio #medchem #proteindegradation #E3ligase
VISHAL FALKE @FALKE_VISHAL
165 Followers 2K Following Oncology Strategist | Unveiling Growth Pathways for Leaders & Innovators in Pharma and Biotech
Sam Klempner @KlempnerSam
3K Followers 652 Following GI medical oncologist focusing on stomach and esophageal cancer research at Massachusetts General Hospital, Harvard Medical School
Adam Feuerstein ✡�.. @adamfeuerstein
114K Followers 750 Following Reporter @statnews. The Harry Kane of biotech. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously.
Jacob Plieth @JacobPlieth
26K Followers 285 Following Journalist @ ApexOnco. The Wolverine Of Biotech / Mr ASH. Once had a blue tick. Interested in: oncology. Not interested in: what stock you bought today.
Raffaele Colombo @raffcolo
927 Followers 507 Following ADCs, targeted therapies, chemistry, biotech, pharma. Associate Director @ Zymeworks
Bertrand Delsuc @BertrandBio
16K Followers 253 Following Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design) & a bit of Bio :)
Paolo Tarantino @PTarantinoMD
22K Followers 537 Following Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs & good music.
@onco_park I love peptides. This list also does not mention the cyclic peptide certepetide being tested in multiple clinical trials (incl. 2 * Ph2b).
Impressive to think at the journey of ADCs over the last 5y. 5 yrs ago today, the only ADC approved for a solid tumor was T-DM1 for HER2+ MBC. 5y later, we have 6 ADCs for solid tumors, 2 more coming, an agnostic ADC & 150+ new ADCs in development. And it’s only just started.
🔥off the press: Durvalumab + gemcitabine/cisplatin in advanced biliary tract cancer: patient-reported outcomes from TOPAZ-1 @TheLancetOncol 👉No improvement yet, but adding Durva has no detrimental effect and some long-term benefit Author link👇 authors.elsevier.com/c/1j02A5EIIgPd… @myESMO…
We’re excited to have entered into an agreement to extend and expand our research collaboration with PeptiDream. Our companies have made tremendous progress in identifying peptides with potential to enable novel radioligand therapies and more, and I look forward to our continued…
Answer: Only <5% of the weight of an ADC is determined by the payload. Examples: - T-DM1: MW 145,000 Da, of which ≈2500 Da related to the payload (738 Da X 3.5 [DAR]) - T-DXd: MW 158,000 Da, of which ≈4000 Da related to the payload (493 Da X 8 [DAR]) @EladSharonMD
What is the contribution of the payload to the molecular weight of a typical ADC?
💯 A way for Asian companies to have a foothold in the US and in the EU.
According to the press release, Ono Pharmaceutical's acquisition of Deciphera can be summarized in three main ways. Deciphera contributes specialized research and development capabilities in kinase drug discovery, robust commercial and sales platforms in the United States and…
So much for "there is no side effects" for #GLP1's
❖ MOST PEOPLE WHO TRY OBESITY MEDS QUIT The majority of patients prescribed weight loss drugs for obesity stop taking them because of side effects and cost, according to the results of a new survey from HealthCentral, a leading digital platform focused on informing and…
@PTarantinoMD Reason 11: free payload exposure. pubmed.ncbi.nlm.nih.gov/34895651/
@onco_park Tissue specific and, most likely, prior treatment specific. Most patients with CRC receive irinotecan before T-DXd. Most patients with breast cancer do not.
Ono Pharmaceuticals acquiring $DCPH for $2.4 billion. investors.deciphera.com/news-releases/…
Destiny-Breast06 hits on PFS, early trend on OS @ IA so we'd have HR+ HER- (<ultralow/LLOQ) HER2+ down to HER2-ultralow TNBC more details & descriptive analysis in HER2-ultralow at #ASCO24 ~20k HER2 receptors/cell in normal epithelial cells vs 20-100k in ultralow cancer cells
T-DXd showed statistically significant and clinically meaningful improvement in PFS in the overall trial population (patients with HER2 low and HER2 ultralow [defined as IHC 0 with membrane staining; IHC >0 <1+] metastatic breast cancer) businesswire.com/news/home/2024…
T-DXd showed statistically significant and clinically meaningful improvement in PFS in the overall trial population (patients with HER2 low and HER2 ultralow [defined as IHC 0 with membrane staining; IHC >0 <1+] metastatic breast cancer) businesswire.com/news/home/2024…
Bispecific T cell engager therapy for refractory rheumatoid arthritis @NatureMedicine nature.com/articles/s4159…
Sunday story from me. Important enough not to wait for Monday. $MOR $NVS New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition statnews.com/2024/04/28/mor…
@PTarantinoMD For maytansinoids (and for any other payload or small molecule), in vitro potency depends on the structure/property of the molecule
Answer: in terms of potency, DM1 (maytansine derivative) >> DXd, SN-38 & doxo. The ⬇️ potency of DXd/SN38, however, allowed to include them in DAR 8 ADCs w/ cleavable linkers, among the reasons why T-DXd > T-DM1 in DB03. europepmc.org/article/pmc/pm… nature.com/articles/s4146… @raffcolo
Which of the following ADC payloads is more potent?
@onco_park Sometimes I am surprised by myself that I remember these things, despite having looked at >500 assets in three last three years in various levels of detail 😅 (humble brag 😄)
@onco_park It’s a while ago I looked at the PSMA RLTs but I believe to remember that there were subtle differences in the tissue distribution (e.g., kidney & liver)
Quelles sont les chances de voir des coquelicots en pleine ville? Cet aprem, dans une rue de Lyon, dans le 8ème. Mystère…🤭 What are the odds? Poppies in a street of #Lyon, France. Not an understatement to say it’s VERY uncommon see them in the middle of cities!
@onco_park “Dose dependent increase in [IFN-gamma] (not shown)”
Trends for United States
You might like
